Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
Heart Fail Clin ; 14(3): 403-411, 2018 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-29966637

RESUMEN

Diffuse pulmonary lung disease and chronic obstructive pulmonary disease is a heterogeneous population that can manifest pulmonary hypertension. These subgroups are classified as primarily World Health Organization group 3. Available data suggest that the impact of pulmonary hypertension targeted therapy in diffuse pulmonary lung disease and chronic obstructive pulmonary disease is limited and survival is poor despite attempted treatment.


Asunto(s)
Hipertensión Pulmonar/etiología , Enfermedades Pulmonares Intersticiales/complicaciones , Enfermedad Pulmonar Obstructiva Crónica/complicaciones , Función Ventricular Derecha/fisiología , Ventrículos Cardíacos/fisiopatología , Humanos , Hipertensión Pulmonar/terapia , Enfermedades Pulmonares Intersticiales/terapia , Enfermedad Pulmonar Obstructiva Crónica/terapia , Disfunción Ventricular Derecha/etiología
2.
Pediatrics ; 120(4): e862-8, 2007 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-17908742

RESUMEN

OBJECTIVES: Mumps is a vaccine-preventable disease that may cause outbreaks. In July 2005, an outbreak of mumps occurred during a children's summer camp in upstate New York. An investigation was initiated to describe the cases and evaluate vaccine effectiveness. METHODS: A retrospective cohort study was conducted among 541 children from the United States and abroad who attended a 1- or 2-month overnight summer camp. Patients with mumps were interviewed; serologic analysis was conducted for 6 case patients. Vaccine effectiveness was calculated by retrospective review of immunization records for 507 attendees who were eligible for vaccination and had verified immunization history. RESULTS: Thirty-one camp attendees were identified as having mumps (attack rate: 5.7%); 5 (83%) of 6 patients tested had positivity for mumps immunoglobulin M. Of the 507 participants (including 29 patients) with available immunization history, 440 (including 16 [87%] patients) were 2-dose recipients of mumps vaccine (attack rate: 3.6%); 46 participants (including 4 [9%] patients) were 1-dose recipients (attack rate: 8.7%); and 21 (including 9 [4%] patients) were unvaccinated (attack rate: 42.9%). Vaccine effectiveness was 92% for 2 doses and 80% for 1 dose. CONCLUSIONS: Outbreaks of mumps in settings such as summer camps can occur despite high vaccination rates. Vaccine effectiveness for 2 mumps vaccinations was greater than vaccine effectiveness for 1 mumps vaccination. Therefore, recommendation of 2 mumps vaccinations for summer camp participants continues to be appropriate. Control of mumps disease relies on broad vaccination coupled with correct clinical diagnosis and strict control measures.


Asunto(s)
Acampada , Brotes de Enfermedades , Vacuna contra la Parotiditis/administración & dosificación , Paperas/epidemiología , Paperas/prevención & control , Adolescente , Adulto , Anciano , Anticuerpos Antivirales/análisis , Niño , Estudios de Cohortes , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Inmunoglobulina M/sangre , Masculino , Persona de Mediana Edad , Virus de la Parotiditis/inmunología , New York/epidemiología , Estudios Retrospectivos , Resultado del Tratamiento , Vacunación/estadística & datos numéricos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA